What second line regimen do you use in a patient with metastatic RAS-mutated, MMR proficient colorectal cancer with disease progression after 12 cycles of FOLFOXIRI+Bev?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Would you offer any adjuvant therapy for a young patient with anal cancer s/p definitive chemoradiation and R0 resection with significant residual disease?

Which PD-1 inhibitor will you use with chemotherapy in initial treatment of patients with metastatic anal cancer?

How should immunotherapy be incorporated into the treatment strategy for patients with resectable stage III microsatellite instability–high (MSI-H) or mismatch-repair-deficient (dMMR) extrahepatic cholangiocarcinoma?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.